Avenue Therapeutics (ATXI)
(Delayed Data from NSDQ)
$6.20 USD
+6.08 (5,199.15%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $6.28 +0.08 (1.29%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Avenue Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 15 | 8 | 4 | 5 | 26 |
Income After Depreciation & Amortization | -15 | -8 | -4 | -5 | -26 |
Non-Operating Income | 4 | 4 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -10 | -4 | -4 | -5 | -26 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -10 | -4 | -4 | -5 | -26 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -10 | -4 | -4 | -5 | -26 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -15 | -8 | -4 | -5 | -26 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -15 | -8 | -4 | -5 | -26 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 10.59 | 2.19 | 1.13 | 1.10 | 1.05 |
Diluted EPS Before Non-Recurring Items | -0.98 | -1.63 | -3.30 | -4.65 | -24.74 |
Diluted Net EPS (GAAP) | -0.98 | -1.63 | -3.30 | -4.65 | -24.74 |
Fiscal Year end for Avenue Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 2.12 | 2.07 | 3.93 | 6.43 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -2.12 | -2.07 | -3.93 | -6.43 |
Non-Operating Income | NA | 2.74 | 2.58 | -0.09 | -1.17 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | 0.62 | 0.51 | -4.02 | -7.60 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | -0.02 | -0.01 | -0.01 | -0.07 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 0.62 | 0.51 | -4.02 | -7.60 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 0.64 | 0.53 | -4.01 | -7.54 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 1.14 | 8.20 | 7.76 | 5.57 |
Diluted EPS Before Non-Recurring Items | NA | 0.56 | 0.06 | -0.52 | -1.37 |
Diluted Net EPS (GAAP) | NA | 0.83 | 0.06 | -0.52 | -1.35 |